NIMH Psychoactive Drug Screening Program

NIMH精神活性药物筛选计划的目的是筛选新的合成化合物和天然产品，作为基础和临床研究的研究工具或探针，作为治疗精神障碍的药物，以及作为脑功能成像的PET、SPECT和fMRI配体。该程序主要用于筛选以前被证明具有与NIMH相关的药理、生化或行为活性的化合物，而不是用于对天然产物或组合库进行大规模随机筛选的目的。然而，也可以对活性未知的合成或天然产物化合物的小型库以及通过NIH资助的HTS或化学计划产生的Hit或Lead化合物进行有限的筛选。化合物将由研究界提供，主要是由NIH支持的研究人员提供。预计承包者将持续不断地收到和筛选大院，尽管每月的请求量会有所不同。

The purpose of the NIMH Psychoactive Drug Screening Program is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as PET, SPECT, and fMRI ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries. However, limited screening may also be conducted on small libraries of synthetic or natural product compounds of unknown activity and on hit or lead compounds generated through NIH-funded HTS or chemistry programs. Compounds will be provided by the research community, primarily NIH-supported investigators. It is anticipated that the Contractor will receive and screen compounds on a continuous and on-going basis, although the volume of requests will vary from month to month.